SCM
CMPX icon

Silverarc Capital Management’s Compass Therapeutics CMPX Stock Holding History

Silverarc Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-172,400
Closed -$912K – 78
2026
Q1 		$912K Buy
+172,400
New +$995K 0.09% 67

Other funds holding CMPX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Silverarc Capital Management's CMPX Position: Q2 2026 in Review

Silverarc Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 859,049 shares — an estimated $4.54M sold.

Silverarc Capital Management first reported a position in CMPX in Q3 2022 and held it in 7 quarters. The position peaked at $9.92M in Q3 2025. 136 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Silverarc Capital Management reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 859,049 Compass Therapeutics shares in Q2 2026, an estimated $4.54M.
  • Silverarc Capital Management first reported a position in Compass Therapeutics in Q3 2022 and held it in 7 quarters.
  • Silverarc Capital Management's Compass Therapeutics position peaked at $9.92M in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.